Financing channel feed

Is CG On­col­o­gy’s IPO a bench­mark for a bet­ter year in pub­lic of­fer­ings? 

Last year

Biotech's 2024 IPO sea­son kicks off with heavy de­mand for CG On­col­o­gy in $380M list­ing

Last year

LB Phar­ma­ceu­ti­cals clos­es $75M Se­ries C as it be­gins PhII schiz­o­phre­nia tri­al

Last year
Startups

Ex­clu­sive: Reid Hu­ber re­unites with for­mer In­cyte col­league Wen­qing Yao, backs Syn­no­va­tion with $102M for three tri­als

Last year
Startups

Gene edit­ing de­liv­ery biotech GenEd­it part­ners with Genen­tech, rais­es an­oth­er $24M

Last year
Startups
Pharma

On­col­o­gy biotech Ac­cent rais­es $75M to en­ter the clin­ic

Last year
Startups

Ar­riVent out­lines plans for $135M IPO in sec­ond biotech list­ing of 2024

Last year
Startups
China

Ex­clu­sive: Two biotechs merge to form Cal­lu­na, with €75M in hand to fo­cus on im­munother­a­py an­ti­bod­ies

Last year
Deals

New­ly hope­ful, bio­phar­ma still faces an un­cer­tain 2024

Last year
Pharma

Re­turn of the SPAC? Bi­hua Chen and Cor­morant go for round two af­ter Moon­Lake suc­cess

Last year

Bridge­Bio rais­es up to $1.2B, a month af­ter sub­mit­ting car­dio drug to FDA

Last year

CG On­col­o­gy aims for $181M list­ing in first biotech IPO of 2024

Last year

In­vest­ment firm Mi­rae launch­es its US biotech VC fund with $50M

Last year

Graphite Bio co-founder de­buts Treg cell ther­a­py start­up with $75M, aims to ‘trick’ im­mune sys­tem in­to re­set­ting

Last year
Startups
Cell/Gene Tx

Ra­tio rais­es $50M as ra­dio­phar­ma field finds its groove

Last year
Startups

Co­manche se­cures $75M to test preeclamp­sia siR­NA in PhII, adds Scott Got­tlieb to board

Last year
Startups

Kyver­na Ther­a­peu­tics files for IPO as au­toim­mune CAR-T space heats up

Last year
Startups
Cell/Gene Tx

Dis­co de­buts with €20M seed round to ad­vance sur­faceome-based plat­form, with sup­port from Ab­b­Vie

Last year
Startups

Mid-stage CNS biotech Al­to Neu­ro­science files for NYSE list­ing

Last year
Startups

Ex­clu­sive: Au­toim­mune CAR-T biotech Kyver­na Ther­a­peu­tics is con­sid­er­ing an IPO next month

Last year
Startups
Cell/Gene Tx

Dyne clos­es $345M pub­lic of­fer­ing a week af­ter ear­ly pos­i­tive da­ta for dy­s­tro­phy drugs

Last year
R&D

Prax­is prices $150M pub­lic stock of­fer­ing ahead of four topline neu­ro read­outs in 2024

Last year

Blue­bird is still look­ing for more fi­nanc­ing as it brings sick­le cell ther­a­py to mar­ket: #JPM24

Last year
Cell/Gene Tx

CNS biotech My­robal­an Ther­a­peu­tics rais­es $24M Se­ries A to en­ter the clin­ic

Last year
Startups
China
First page Previous page 20212223242526 Next page Last page
A service from the Financial Times